(1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate, and pharmaceutical composition in which it the compound is comprised

• Main Authors: ANDINO MARTA MARIA, FIESE EUGENE FRED, SINAY TERRY GENE
• Format: Patent
• Language: Czech; English
• Published: 15.02.2006
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Trihydrát methansulfonátu (1S,2S)-1-(4-hydroxyfenyl)-2-(4-hydroxy-4-fenylpiperidin-1-yl)-1-propanolu; farmaceutický prostredek pro lécbu poruch zvolených ze souboru zahrnujícího degenerativní poruchycentrálního nervového systému (CNS), jako je mrtvice, Alzheimerova choroba, Parkinsonova choroba, Huntingtonova choroba; epilepsii, úzkost, cerebrální ischemii, svalové krece, multiinfarktovou demenci, traumatické poskození mozku, bolest, demenci spojenou s AIDS, hypoglykemii, migrénu, amyotrofickou laterální sklerózu, návyk na drogy a alkohol, symptomy po odnetí drogy nebo alkoholu, psychotické stavy a urinární inkontinenci u savcu s jeho obsahem; farmaceutická kombinace obsahující tuto slouceninu a cinidlo schopné obnovit rovnováhu excitacnízpetné vazby z ventrálního laterálního jádra thalamu do kortexu. The present invention relates to the trihydrate of the mesylate salt of (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol; a pharmaceutical composition pharmaceutical compositions containing it and intended for treating disorders being selected from the group consisting of degenerative central nervous system (CNS) disorders such as stroke, Alzheimer's disease, Parkinson's disease and Huntington's disease; epilepsy, anxiety, cerebral ischemia, muscular spasms, multiinfarct dementia, traumatic brain injury, pain, AIDS related dementia, hypoglycemia, migraine, amyotrophic lateral sclerosis, drug and alcohol addiction, drug and alcohol withdrawal symptoms, psychotic conditions and urinary incontinence in a mammal. Disclosed is also a pharmaceutical composition containing the above-described compound and an agent capable of restoring the balance of the excitatory feedback from the ventral lateral nucleus of the thalamus into the cortex.